Pfizer is a global biopharmaceutical company that develops and manufactures innovative medicines and vaccines to improve health outcomes for people around the world. Renowned for its extensive research and development efforts, Pfizer focuses on various therapeutic areas including vaccines, oncology, immunology, cardiology, endocrinology, and rare diseases. The company is committed to addressing significant health challenges through the discovery of new treatments, leveraging cutting-edge science and technology. Pfizer also emphasizes partnerships and collaborations to expand its capabilities and enhance access to healthcare solutions. Read More
Animal health company Zoetis (NYSE:ZTS) reported Q1 CY2025 results topping the market’s revenue expectations, with sales up 1.4% year on year to $2.22 billion. The company’s full-year revenue guidance of $9.5 billion at the midpoint came in 1.8% above analysts’ estimates. Its non-GAAP profit of $1.48 per share was 5.8% above analysts’ consensus estimates.
President Donald Trump signed an executive order Monday directing the FDA to accelerate approvals for domestic pharmaceutical manufacturing facilities as his administration prepares to announce new tariffs on imported medicines within two weeks
LONDON - April 30, 2025 - PRLog -- Kwizda Pharma, a division of Kwizda Holding GmbH and a leader in the Austrian healthcare market, has selected the CARA Life Sciences Platform from Generis, leading provider of CARA Platform for Content and Data management, to digitise and streamline Quality processes.With over 170 years of experience in the pharmaceutical industry, Kwizda Pharma develops proprietary over-the-counter (OTC) drugs and operates as a Contract Manufacturing Organisation (CMO). Kwizda Pharma required a system to upgrade from paper-based and manual processes such as MS Excel trackers for managing quality documentation and training, which led to inefficiencies in compliance tracking, audits, and quality management reviews."Maintaining an up-to-date and compliant quality system was becoming increasingly difficult," states Desiree Womser-Matlschweiger, Head of QA at Kwizda Pharma. "Training management, in particular, posed significant challenges, as tracking employee training and physical signatures was a time-consuming process."Kwizda Pharma selected the CARA Life Sciences Platform for its out-of-the-box (OOTB) configuration, rapid implementation timeline due to minimal additional validation, and cost-effectiveness for smaller companies. The company needed a solution that would allow a seamless transition from paper-based workflows without the burden of lengthy customisations. Additionally, as a CMO, the ability to securely include external collaborators on the platform was an important factor in the selection process."CARA's pre-validated, fully compliant solution was ideal for us, as it reduces the burden internally to handle system validation," Desiree added. "The responsiveness and expertise of the Generis team made for an incredibly smooth selection process; they understood our needs and made the choice simple."Phase one of the implementation focuses on quality document management and read & understood training workflows, this is set to go live by the end of June. The second phase of the implementation, planned for later this year, will expand the system's capabilities to include a full Quality Management System (QMS) and advanced Learning Management System (LMS) features. Kwizda Pharma also intends to integrate its ERP system to further enhance operational efficiency. By choosing CARA, Kwizda Pharma can consolidate different systems and move away from paper-based processes.The company looks forward to improved audit readiness and overall quality oversight with the CARA Life Sciences Platform. "Audits are currently quite challenging with our paper-based processes. With CARA, we anticipate a more efficient and transparent audit process, allowing us to focus on continuous improvement." Added Desiree.By eliminating manual workflows and paper-based processes, Kwizda Pharma expects to see significant efficiency gains across its quality operations. The latest CARA version also includes the 'AI Assistant' which will enable Kwizda Pharma to easily incorporate AI use in the future. The CARA Life Sciences Platform will provide real-time visibility into quality metrics, reduce the administrative burden of compliance management, and ensure seamless collaboration both internally, and with external partners.About GenerisGeneris is a UK-headquartered developer of world-class data, content and business process management for regulated industries globally. 60% of the top 20 life sciences companies rely on Generis' flagship CARA™ Life Sciences Platform, including AbbVie, UCB, Biogen, Reckitt, Bristol Myers Squibb, Bayer, Pfizer, and Merck KGaA. Today Generis serves more than 750,000 users worldwide, across use cases ranging from RIM, Regulatory / R&D and Safety to Clinical, Non-clinical, Quality GxP, CMC, Pharmacovigilance, Medical Information / Medical Affairs applications and more. More at www.caralifesciences.generiscorp.com .About Kwizda PharmaKwizda Pharma is a division of Kwizda Holding GmbH, a family-run Austrian company with a long-standing reputation in the healthcare sector. With more than 170 years of experience, Kwizda Pharma develops proprietary over-the-counter (OTC) drugs and provides pharmaceutical services ranging from development to supply. The company operates internationally and also functions as a Contract Manufacturing Organisation (CMO), supporting high-quality pharmaceutical production and distribution.
The S&P 500 (^GSPC) is home to the biggest and most well-known companies in the market, making it a go-to index for investors seeking stability.
But not all large-cap stocks are created equal - some are struggling with slowing growth, declining margins, or increased competition.
Viking's leading drug candidate could be a blockbuster in the weight loss market, which experts believe could grow to $150 billion over the coming years.
It’s easy to understand why income investors are interested in Pfizer. With a current yield of 7.1%, it’s one of the highest-yielding stocks in the S&P 500. Let’s dig into the dividend and see whether it’s in any better shape than the stock.
Goldman Sachs keeps Neutral on Pfizer, citing unclear product growth plans and focus on M&A amid changing market valuations and national security concerns.
Curious about the most active S&P500 stocks in today's session? Get insights into the stocks that are leading the way in terms of trading volume and market attention.
(BPT) - Content sponsored and provided by Pfizer. Ashley partnered with Pfizer to share her experience living with moderate to severe rheumatoid arthritis (RA).
U.S. stock futures are down Wednesday morning, despite major averages ending up on Tuesday, and the S&P 500 and Dow Jones notching their sixth-straight day in the green, the longest streak for the indexes in months.
